This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by Rönnblom, L Articles by Pascual, V PubMed PubMed Citation Articles by Rönnblom, L Articles by Pascual, V Social Bookmarking                   What's this?

The innate immune system in SLE: type I interferons and dendritic cells

Section of Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden

V Pascual

Baylor Institute for Immunology Research, Dallas, Texas, USA

Patients with systemic lupus erythematosus (SLE) have an increased expression of type I interferon (IFN) regulated genes because of a continuous production of IFN-. The cellular and molecular background to this IFN- production has started to be elucidated during the last years, as well as the consequences for the innate and adaptive immune systems. Plasmacytoid dendritic cells (pDC) activated by immune complexes containing nucleic acids secrete type I IFN in SLE. Type I IFN causes differentiation of monocytes to myeloid-derived dendritic cell (mDC) and activation of autoreactive T and B cells. A new therapeutic option in patients with SLE is, therefore, inhibition of IFN-, and recent data from a phase I clinical trial suggests that administration of neutralizing monoclonal antibodies against anti-IFN- can ameliorate disease activity.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?